TriSalus Life Sciences (TLSIW) Asset Writedowns and Impairment (2024 - 2025)
TriSalus Life Sciences (TLSIW) reported Asset Writedowns and Impairment of $34000.0 for Q3 2025, down 40.35% quarter-over-quarter from $57000.0 in Q2 2025.
TriSalus Life Sciences (TLSIW) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
TriSalus Life Sciences has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $34000.0 in Q3 2025.
- For the quarter ending Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $34000.0; the trailing twelve-month figure through Sep 2025 stood at $317000.0 (changed N/A YoY), and the FY2024 full-year result was $187000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q3 2025 stood at $34000.0, down from $57000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $187000.0 in Q4 2024, with the low at $34000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | TriSalus Life Sciences | - | - | 7.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 34,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Mar 31, 2025 | 39,000.00 |
| Mar 31, 2025 | 39,000.00 |
| Dec 31, 2024 | 187,000.00 |
| Dec 31, 2024 | 187,000.00 |